Moreover, diverse in vivo experiments including validation of therapeutic efficacy of HsA (with sorafenib) in xenograft animals, pharmacokinetics and tissue distribution study to predict dosage of HsA, and toxicological properties of HsA are also required for developing HsA as a complementary candidate against HCC in human. The gene discussed is ALB; the disease is hepatocellular carcinoma.